Grant: Idea to Innovation
Université de Sherbrooke
$20,000.00
L2M NSERC - One Health-compatible antibiotic for dairy farms / Nouvel antibiotique pour les fermes laitières compatible avec le concept d'une Seule Santé
EF 2023-24
Résumé
The Canadian dairy industry is vital to the agriculture sector, with a total net farm cash receipts of $8.23 billion. There are approximately 10,000 dairy farms in Canada and over 44,000 jobs are dependent on this industry. A recurrent problem is bovine mastitis, an inflammatory disease of the udder caused by bacterial infections. The most common and problematic pathogen is Staphylococcus aureus. The economic burden is due to additional expenditures on mastitis prevention, treatment, and losses due to reduced milk production, cows culling and discarded milk. With an estimated cost of $662 per cow annually and 1.39 million dairy cows in Canada, the economic losses totalize over $800M in Canada and over $2 Billions USD in the USA annually. Mastitis is the main cause of antibiotic use in dairy farms, but effective antibiotic treatments are now strongly limited, due to antimicrobial resistance and to the recent implementation of restrictive national legislation. Clinically important category 1 antibiotics like ceftiofur, which represented the most common treatment for mastitis, are now strongly restricted for animal use. While this is desirable from a clinical perspective because it reduces the emergence of antibiotic resistance, there is now an unmet need for antibiotics dedicated to mastitis. We have developed a novel class of antibiotics having an unprecedented mode of action and that is highly specific against S. aureus. Its narrow antibiotic spectrum ensures its exclusive use for S. aureus-induced mastitis and will not be subject to category 1 restrictions. In addition to being as effective as the competition, no common resistance mechanism currently exists against this new class, unlike currently available antibiotics. Our antibiotic class is stable in solution at room temperature and will be packaged in a convenient ready-to-use syringe for direct injection into the infected quarter, similarly to existing treatments.The grant is requested for the entrepreneurship training of a graduating doctoral student, for producing a market assessment report and for intellectual property protection as first steps in taking our novel antibiotic to market. La subvention est demandée pour la formation en entrepreneuriat d'un doctorant diplômé, pour la production d'un rapport d'évaluation du marché et pour initier la protection de la propriété intellectuelle comme premières étapes de la commercialisation de notre nouvel antibiotique.
Programme
Idea to Innovation
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
590712-2024
Name nom
Malouin, Francois F
Department département
Biologie
Organization id
68
Institution établissement
Université de Sherbrooke
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2023
Competition year année de concours
2024
Award amount
20000
Program id
I2IPJ
Program name en
Idea to Innovation
Program name fr
De l'idée à l'innovation
Group en
RESEARCH PARTNERSHIPS
Group fr
PARTENARIATS DE RECHERCHE
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
505
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Veterinary pharmaceuticals
Area of application fr
Produits pharmaceutiques à usage vétérinaire
Research subject code
5200
Research subject group en
Microbiology
Research subject group fr
Microbiology
Research subject en
Microbiologie
Research subject fr
Microbiologie
Application title
L2M NSERC - One Health-compatible antibiotic for dairy farms / Nouvel antibiotique pour les fermes laitières compatible avec le concept d'une Seule Santé
Keyword
Antibiotic resistance; Antibiotic use restriction; Dairy farms; Infectious bovine mastitis; Novel antibiotic class; One Health; Staphylococcus aureus
Application summary
The Canadian dairy industry is vital to the agriculture sector, with a total net farm cash receipts of $8.23 billion. There are approximately 10,000 dairy farms in Canada and over 44,000 jobs are dependent on this industry. A recurrent problem is bovine mastitis, an inflammatory disease of the udder caused by bacterial infections. The most common and problematic pathogen is Staphylococcus aureus. The economic burden is due to additional expenditures on mastitis prevention, treatment, and losses due to reduced milk production, cows culling and discarded milk. With an estimated cost of $662 per cow annually and 1.39 million dairy cows in Canada, the economic losses totalize over $800M in Canada and over $2 Billions USD in the USA annually. Mastitis is the main cause of antibiotic use in dairy farms, but effective antibiotic treatments are now strongly limited, due to antimicrobial resistance and to the recent implementation of restrictive national legislation. Clinically important category 1 antibiotics like ceftiofur, which represented the most common treatment for mastitis, are now strongly restricted for animal use. While this is desirable from a clinical perspective because it reduces the emergence of antibiotic resistance, there is now an unmet need for antibiotics dedicated to mastitis. We have developed a novel class of antibiotics having an unprecedented mode of action and that is highly specific against S. aureus. Its narrow antibiotic spectrum ensures its exclusive use for S. aureus-induced mastitis and will not be subject to category 1 restrictions. In addition to being as effective as the competition, no common resistance mechanism currently exists against this new class, unlike currently available antibiotics. Our antibiotic class is stable in solution at room temperature and will be packaged in a convenient ready-to-use syringe for direct injection into the infected quarter, similarly to existing treatments.The grant is requested for the entrepreneurship training of a graduating doctoral student, for producing a market assessment report and for intellectual property protection as first steps in taking our novel antibiotic to market. La subvention est demandée pour la formation en entrepreneuriat d'un doctorant diplômé, pour la production d'un rapport d'évaluation du marché et pour initier la protection de la propriété intellectuelle comme premières étapes de la commercialisation de notre nouvel antibiotique.